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More than 50% of patients with gastric cancer are inoperable at the time of diagnosis.
1,2
The resectability rate ranges from 31 to 66%, and the 5-year survival rate ranges from 5 to
15%.
2 Malignant obstruction develops frequently in advanced gastric cancer, mainly in the
gastric outlet and duodenum.
3 However, colonic obstruction has occasionally been
reported in cases of advanced gastric cancer with carcinomatosis or colonic invasion.
4,5
Terminally ill patients with malignant bowel obstruction often present with nausea,
vomiting and constipation, resulting in reduced oral intake and a negative impact on the
patient’s quality of life.
6 Therefore, intestinal obstruction usually requires treatment by
emergency surgery or stent insertion. Decompressive surgery is the first-line therapy for
the palliation of symptomatic patients. However, palliative surgery is associated with high
morbidity and mortality, and the results of surgery are not always satisfactory.
7
Gastrointestinal stent insertion is performed as a palliative effort to improve the quality
of life for inoperable cancer patients with gastrointestinal obstruction. Endoscopic stent
placement has been reported as a feasible, safe, and effective alternative in patients with an
especially short life expectancy, advanced disease stage, and poor general condition.
8
Endoscopic stenting was introduced 40 years ago for the treatment of malignant
obstruction using polyethylene prostheses.
9 In recent years, self-expandable metal stents
(SEMS) have emerged as a simple therapeutic option for non-resectable malignant
intestinal obstruction. The ideal stent should have a large internal diameter to ensure the
passage of a normal diet, and should be flexible and nontraumatic when fully expanded. It
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fixed in its position.
10
On the other hand, there are several complications associated
with stent insertion, including bowel perforation, stent
migration, bleeding, abdominal pain, and reobstruction. The
causes of reobstruction include tumor growth, stent migration
and fecal impaction, with the main cause of obstruction due to
cancer growth blocking the stent lumen or growing around the
lumen.
11
We report a case of advanced gastric cancer with carcino-
matosis, in which colonic reobstruction was treated by recurrent
colonic stent insertion at the same site of transverse colon. This
patient maintained a good general condition, allowing for the
continuation of chemotherapy.
A 67-year-old woman was admitted with constipation and
abdominal pain lasting for 5 days and a history of large bowel
obstruction and two previous transverse colonic stent insertions.
A plain abdominal radiograph showed dilated large bowel
loops. The patient had undergone radical subtotal gastrectomy
with gastrojejunostomy 5 years earlier.
The patient’s pathological stage was T3N0M0 (stage II).
After the operation, 12 cycles of 5-floururacil and adriamycin
were administrated for adjuvant chemotherapy. After 3 years,
the patient was diagnosed with cancer recurrence in the trans-
verse colon and carcinomatosis, along with the development of
colonic obstruction. On colonoscopy, two uncovered colonic
stents (Niti-S D type, Taewoong Inc., Seoul, Korea) were
inserted in the obstructed transverse colon, followed by a pallia-
tive treatment of 10 cycles of 5-floururacil and oxaliplatin
chemotherapy.
Ten months after the first stent insertion, the patient showed
signs of intestinal reobstruction. Upon examination of the
previous stent, we observed on colonoscopy that the malignant
tumor had grown into the stent, therefore, we inserted a 10 cm-
sized Nitinol covered stent (Niti-S Comvi, Taewoong Inc.,
Seoul, Korea). The patient’s disease progressed, and we chang-
ed the chemotherapy regimen to paclitaxel.
Two months following the reinsertion of the colonic stent, the
patient again developed increasing abdominal pain and
constipation. Nasogastric Levin tube decompression was admi-
nistered for 1 week, but the bowel obstruction was not improved.
On colonoscopy, the new stent was found to remain in place.
However, there was a tumor growth into the stent. Finally, a 9
cm-sized Wallflex uncovered colonic stent (Boston Scientific,
MA, USA) was inserted at the same site (Figs. 1 and 2).
The procedure decompressed the bowels, and the general
condition of the patient improved, allowing her to continue with
chemotherapy after 6 months. Although the prognosis of recurrent
gastric cancer with carcinomatosis is extremely poor, this case
demonstrates that supportive care, such as three recurrent colonic
stent insertions, may help maintain a generally good condition to
allow for the continuation of chemotherapy. (Fig. 3)
For malignant obstructive cancer patients, the board of direc-
tors of the European Association for Palliative Care (EAPC)
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Fig. 1.Abdominal X-ray before 3
rdcolonic stent. Fig. 2.Abdominal X-ray after  3
rdcolonic stent.recommends surgery in patients with poor prognostic criteria
such as intra-abdominal carcinoma, poor performance status,
and massive ascites.
6
Endoscopic intervention is an effective and relatively safe
palliative modality for patients with inoperable gastrointestinal
cancer. In 1991, Dohmoto first described palliative stenting for
colorectal obstruction.
12,13 Colonic stenting as a palliative aim or
a bridge to surgery for malignant colorectal obstruction is less
invasive, and is associated with lower morbidity than emergency
surgery. A recent study showed that palliative malignant colonic
stenting, when compared to surgical decompression, offers not
only shorter times for oral intake and hospital stay, but also less
frequent complications. Furthermore, there was no procedure-
associated mortality.
4 In contrast, the morbidity and mortality
rates for colonic surgical bypass ranges from 9% to 39.5% and
7.5% to 20.4%, respectively.
14
The use of SEMS could be the treatment of choice in malig-
nant obstructive cancer patients who are in a generally poor
condition. Self-expandable stents are made of metal alloys, can
be covered or uncovered, and have varying sizes and shapes.
An uncovered stent is limited by tumor ingrowth through the
gaps in the stent mesh. Covered stents provide several advan-
tages; they prevent tumor ingrowth, and have no need for pre-
dilation with a balloon, and are easy to insert. However, higher
incidence of migration with a covered stent has been reported.
7
A systematic review, including 15 comparative studies,
showed stenting to relieve malignant colorectal obstruction: the
median rate of technical success was 96.2%, ranging from
66.6% to 100%, that of clinical success was 92%, ranging from
46% to 100%, and complication rated up to 30%. In the
palliative population, the median duration of stent patency was
106 days (range, 68-288 days).
15,16 Another study reported a
median survival of 1.6 months after stent insertion in 35
malignant cancer patients with bowel obstruction.
6
Our patient showed improved conditions for 2 years after the
recurrence of cancer as carcinomatosis. At first, our patient was
disease-free for 3 years after the postoperative adjuvant chemo-
therapy of 12 cycles of 5-floururacil and adriamycin. At that
time, the patient was tolerant to chemotherapy. Then, her
disease recurred and the first colonic stents were inserted.
Subsequently, she started with palliative chemotherapy, includ-
ing oxaliplatin, and presented with nausea, vomiting, peripheral
neuropathy and anorexia as side effects. No major adverse
effects were observed. Nevertheless, her disease progressed 10
months after the initiation of palliative chemotherapy with
oxaliplatin. The chemotherapy regimen was changed to paclita-
xel and a second colonic stent was reinserted. Although the
patient experienced mild dizziness during the Paclitaxel
treatment, she was still very tolerant of chemotherapy. Until the
reobstruction of the previously inserted second colonic stent, her
Eastern Cooperative Oncology Group (ECOG) performance
status was grade 1. When colonic obstruction developed again
at the same site after the second time, the patient’s performance
status decreased to grade 3 on the ECOG scale. A third stent
was inserted into the obstructed colon. Fortunately, the patient
never experienced complications, such as bleeding, perforation,
or severe abdominal pain from the three stent insertions.
Finally, the patient recovered from the malignant obstruction
and her status improved to grade 1 on the ECOG performance
scale. Thereafter, she continued to being treated by paclitaxel
chemotherapy for 4 months.
This case shows that colonic stenting relieves malignant
colonic obstruction and can help a patient maintain a tolerable
condition for chemotherapy, ultimately improving their chances
for survival.
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